In 2020, Hamid et al. claimed that prior to the CD45-based subtraction of hematogenous cells, CTC enrichment with both EpCAM and CK markers enabled the authors to relate CRC staging with CTC morphological and phenotype features [102]. The gene discussed is EPCAM; the disease is colorectal carcinoma.